BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220321
DTEND;VALUE=DATE:20220323
DTSTAMP:20260516T010134
CREATED:20211125T120837Z
LAST-MODIFIED:20211125T133706Z
UID:32219-1647820800-1647993599@www.pharmajournalist.com
SUMMARY:SMi Presents the 16th Annual Conference: Parallel Trade 2022
DESCRIPTION:SMi’s 16th Annual Conference\nParallel Trade\n21-22 March\, 2022 | Conference\nhttp://parallel-trade.com/pharmajournalistwl \nNAVIGATING THE CHALLENGES AND LEGAL LANDSCAPES OF PARALLEL TRADE \nSMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe\, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade. \nThe 2022 event will be more significant than ever before due to the transition period follow Brexit now also coming to an end. As such\, the UK will no longer be part of the EU free market. This will mean increased medicines prices\, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment\, exhaustion of rights will cease to apply to the UK\, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution. \nThis conference will bring together industry experts to discuss the challenges and drivers of the industry\, including the EU regulatory landscape and the impact of the Brexit and the Pandemic together. The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states. \nBenefits of Attending: \n\nDiscover the impact of Covid-19 on Parallel trade as countries begin to release restrictions. How has the sector been influenced?\nEngage in discussions on the growth within parallel trade over the past year at the only Parallel Trade specific conference within the EU.\nDiscuss the impact on UK parallel trade following Brexit\, through the eyes of regulators\, the pharmaceutical industry and academics\nDevelop further understanding of the rules and regulation changes over the past 12 months\, Parallel Trade\, where are we now?\n\nWho Should Attend: \nVice President/ Heads of/General Managers:\n• International Trade and Relations\n• Supply Chain Development – Brexit\n• Brexit Implementation\n• Market Access\n• Supply Chain Manager\n• Parallel trade reporting\n• Regulatory Affairs\n• IP\n• Purchasing\n• Policy Patent Operations\n• European Affairs\n• Supply and Demand\n• Attorney\n• Distribution \nPlease visit http://parallel-trade.com/pharmajournalistwl for more information\, to download the full agenda\, or to register your place.  If you would like to speak to someone about the event please contact Alia Malick amalick@smi-online.co.uk or call +44 (0)20 7827 6168.
URL:https://www.pharmajournalist.com/event/smi-presents-the-16th-annual-conference-parallel-trade-2022/
LOCATION:Virtual Conference: Online Access Only
ORGANIZER;CN="Hanson Wade":MAILTO:rjones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220322
DTEND;VALUE=DATE:20220325
DTSTAMP:20260516T010134
CREATED:20211111T123644Z
LAST-MODIFIED:20211111T123644Z
UID:32053-1647907200-1648166399@www.pharmajournalist.com
SUMMARY:GPCRs - Targeted Drug Discovery Summit
DESCRIPTION:The inaugural GPCRs – Targeted Drug Discovery Summit has been established to tap into new drug discovery opportunities in undrugged and orphaned GPCRs by better understanding the complex signaling GPCR pathway\, leveraging new structural and genetic data as well as\, emerging screening tools and technologies and up and coming modalities. \nDiscover data driven case studies that showcase the challenges\, learnings and takeaways currently being faced by large pharma\, biotech and academia who are innovating their discovery and development approaches to drug a wider spectrum of clinically relevant but poorly characterized or undrugged GPCRs across a broad range of therapeutic areas such as oncology\, age-related diseases and beyond. \nWhether you are looking to harness the power of structural biology tools or emerging technologies\, join fellow directors\, heads and VPs of drug discovery\, structural biology\, and pharmacology at the GPCRs – Targeted Drug Discovery Summit – the most comprehensive and dedicated scientific and networking forum for innovative biopharma and research institutes to seize the therapeutic opportunities of GPCRs. \nTo know more visit: https://ter.li/d9fxmw
URL:https://www.pharmajournalist.com/event/gpcrs-targeted-drug-discovery-summit/
LOCATION:DoubleTree Suites Boston-Cambridge\, 400 Soldiers Field Rd\, Boston\, MA\, 02134\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220322
DTEND;VALUE=DATE:20220325
DTSTAMP:20260516T010134
CREATED:20211214T012807Z
LAST-MODIFIED:20220124T113103Z
UID:32513-1647907200-1648166399@www.pharmajournalist.com
SUMMARY:STING & TLR-Targeting Therapies
DESCRIPTION:The 3rd STING & TLR-Targeting Therapies Summit is coming at a timely inflection point in this field. \nWith multiple TLR agonists moving into the clinic\, STING agonists exposing new challenges\, multiple approvals on the horizon\, and more novel targets & combinations currently undergoing exciting pre-clinical validation than ever before\, this unique and highly anticipated industry-focused meeting will unite experts in innate immunity to overcome the barriers it faces and accelerate clinical breakthrough. \nReturning in-person to the biopharma hub of Boston\, 30+ expert speakers will take you through case-study led presentations\, juicy panel discussions and live Q&A’s\, all tailored to suit your TLR\, STING & other PRR targeting needs. \nGain connections and insights to plan how to optimize the development of your innate immune agonists into the clinic and overcome obstacles that may impede the delivery of more selective\, better-tolerated medicines to improve survival rates in difficult-to-treat cancers. \nTo know more visit: https://ter.li/z3s9wq
URL:https://www.pharmajournalist.com/event/sting-tlr-targeting-therapies/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR